Daiwa Securities Group Inc. boosted its stake in Amgen, Inc. (NASDAQ:AMGN) by 0.7% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 38,048 shares of the medical research company’s stock after purchasing an additional 258 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Amgen were worth $7,362,000 at the end of the most recent quarter.
A number of other large investors also recently added to or reduced their stakes in AMGN. Advisors Preferred LLC purchased a new position in shares of Amgen in the 2nd quarter worth about $30,000. Arbor Wealth Management LLC raised its position in shares of Amgen by 154.5% in the 2nd quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock worth $31,000 after purchasing an additional 102 shares during the last quarter. Atwater Malick LLC purchased a new position in shares of Amgen in the 3rd quarter worth about $39,000. Ashburton Jersey Ltd purchased a new position in shares of Amgen in the 2nd quarter worth about $42,000. Finally, Strategic Blueprint LLC purchased a new position in shares of Amgen in the 3rd quarter worth about $45,000. Institutional investors and hedge funds own 76.33% of the company’s stock.
Several research firms have recently issued reports on AMGN. BMO Capital Markets set a $240.00 price target on Amgen and gave the stock a “buy” rating in a research report on Monday, September 30th. Morgan Stanley decreased their target price on Amgen from $211.00 to $207.00 and set an “overweight” rating for the company in a research report on Monday, July 15th. Evercore ISI reissued a “hold” rating on shares of Amgen in a research report on Sunday, August 11th. BidaskClub raised Amgen from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $225.00 target price (up previously from $202.00) on shares of Amgen in a research report on Friday, August 16th. Ten analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Amgen currently has a consensus rating of “Buy” and a consensus target price of $219.56.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, October 29th. The medical research company reported $3.66 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.53 by $0.13. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.63 billion. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The business’s quarterly revenue was down 2.8% compared to the same quarter last year. During the same period in the previous year, the company posted $3.69 EPS. Sell-side analysts anticipate that Amgen, Inc. will post 14.44 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 6th. Shareholders of record on Friday, November 15th will be paid a dividend of $1.45 per share. The ex-dividend date is Thursday, November 14th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.62%. Amgen’s dividend payout ratio is currently 40.28%.
In related news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $206.70, for a total transaction of $413,400.00. Following the completion of the transaction, the director now directly owns 16,336 shares in the company, valued at approximately $3,376,651.20. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $215.45, for a total value of $91,566.25. Following the transaction, the director now owns 5,413 shares of the company’s stock, valued at $1,166,230.85. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,851 shares of company stock valued at $3,685,674. Corporate insiders own 0.25% of the company’s stock.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Further Reading: Conference Calls and Individual Investors
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.